You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
First approved treatment in children with multiple sclerosis slows brain atrophy
  1. Arman Eshaghi1,2
  1. 1 Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, University College London, London, UK
  2. 2 Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, London, United Kingdom
  1. Correspondence to Dr Arman Eshaghi, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London WC1B 5EH, UK; a.eshaghi{at}ucl.ac.uk

https://doi.org/10.1136/jnnp-2019-322519

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Fingolimod reduces disease activity and slows brain atrophy in children with multiple sclerosis (MS)

    MS is a common disease in young adults but rare in children. More than a dozen treatments have been approved by the US Food and Drug Administration for treating MS in adults, and several of these treatments are prescribed in children. However, high-quality targeted evidence for children has been lacking. A recent phase III double-blind randomised controlled trial of fingolimod (PARADIGMS) versus interferon beta-1a was the first to show that fingolimod significantly reduced the relapse rate by 82% and the appearance of new or enlarging lesions on T2-weighted MRI by 53%. These benefits came at the cost of more serious adverse events in children with …

    View Full Text

    Footnotes

    • Twitter @es_arman

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests I have received funding for travel from the US National Multiple Sclerosis Society, speaker’s honorarium (paid to my institution) from Biogen and At The Limits educational programme.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles